KR20130113325A - 화장품 및 의약품 적용의 사용에 적합한 국소 투여된, 피부-침투성 글리코사미노글리칸 제형 - Google Patents
화장품 및 의약품 적용의 사용에 적합한 국소 투여된, 피부-침투성 글리코사미노글리칸 제형 Download PDFInfo
- Publication number
- KR20130113325A KR20130113325A KR1020127032320A KR20127032320A KR20130113325A KR 20130113325 A KR20130113325 A KR 20130113325A KR 1020127032320 A KR1020127032320 A KR 1020127032320A KR 20127032320 A KR20127032320 A KR 20127032320A KR 20130113325 A KR20130113325 A KR 20130113325A
- Authority
- KR
- South Korea
- Prior art keywords
- glycosaminoglycan
- skin
- hyaluronan
- glycosaminoglycans
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01212—Hyaluronan synthase (2.4.1.212)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
도 1은 본 발명의 히알루로난-포스파티딜에탄올아민 결합체(HA-PE-1)의 적용 후, 변형되지 않은 히알루로난 및 인산염완충액 대조군과 비교하여, 증가한 히알루로난 세포 껍질을 나타내는 인간 진피 섬유아세포의 현미경 사진이다. 대표적인 히알루로난 세포 껍질은 각 영상에서 화살표로 나타내었다.
도 2는 세포 껍질을 가지는 인간 섬유아세포의 백분율에 대해 처리되지 않은 세포에 히알루로난 단독으로 처리된 섬유아세포와 비교하여, 본 발명의 변형된 히알루로난 조성물(HA-PE-1)의 효과를 나타내는 도이다.
도 3은 히알루로난 세포 껍질의 크기에 대해 변형되지 않은 히알루로난을 처리한 세포와 비교하여, 본 발명의 변형된 히알루로난 조성물(HA-PE-1)의 효과를 나타내는 도이다.
도 4는 본 발명의 히알루로난-포스파티딜에탄올아민 결합체(HA-PE-1), 변형되지 않은 히알루로난 및 완충액(대조군)으로 처리한 후, 히알루로난 껍질을 가지는 히알루로난 수용체(RHAMM-/-, CD44-/- 또는 RHAMM-/-: CD44-/-) 없이 유전자 변형된 마우스 배아 섬유아세포의 수의 차이를 나타내는 도이다. 처리된 섬유아세포로부터의 대표 현미경 사진은 도 5에 나타내었다.
도 5는 본 발명의 히알루로난-포스파티딜에탄올아민 결합체(HA-PE-1), 변형되지 않은 히알루로난 및 완충액(대조군)으로 처리한 후, 히알루로난 껍질을 가지는 히알루로난 수용체(RHAMM-/-, CD44-/- 또는 RHAMM-/-: CD44-/-) 없이 유전자 변형된 마우스 배아 섬유아세포의 대표 현미경 사진이다.
도 6은 본 발명의 변형된 히알루로난 조성물이 함께 사용했을 때 SKL 카탈라제의 효과를 향상시키는 것을 입증하는, SKL 카탈라제, 히알루로난-포스파티딜에탄올아민 결합체(HA-PE-1) 및 SKL 카탈라제와 HA-PE-1의 조합으로 처리된 인간 섬유아세포의 현미경 사진이다.
도 7은 본 발명의 히알루로난-포스파티딜에탄올아민 결합체(HA-PE-1)를 4일 동안 처리하여 국소 적용 후 본 발명의 조성물의 피부장벽을 침투하는 능력을 나타내는 마우스로부터의 피부의 현미경 사진이다. 영상 71(GA-PE-1) 및 73(대조군)은 "["로 표시된 각질생성세포와 함께 20X 확대에서 피부층을 설명한다. 영상 72(처리군) 및 74(대조군)은 화살표로 강조된 대표적인 각질생성세포와 함께 40X 확대에서 피부층을 설명한다.
도 8은 본 발명의 히알루로난-포스파티딜에탄올아민 결합체(HA-PE-1)를 포함하는 크림의 처리 4일 후에 마우스의 피부장벽을 침투하고 각질형성세포 층에서 유지되는 능력을 정량화한 그래프이다. 이 그래프는 도 7에 나타낸 현미경 사진을 정량화한다.
도 9는 4일 동안 처리 후 본 발명의 히알루로난-포스파티딜에탄올아민 결합체(HA-PE-1), 히알루로난과 레시틴의 혼합물(HA+PE), 또는 히알루로난 단독으로 식이요법한 마우스의 피부를 비교한 현미경 사진이다. 각 영상에서 각질형성세포 층은 화살표로 나타내었다. 또한, 4일째에 처리 중단 후, 7일 째에 얻은 피부 샘플의 현미경 사진을 나타내었다.
도 10은 히알루로난과 레시틴의 혼합물(HA+PE) 및 히알루로난 단독 처리된 마우스와 비교하여, 마우스의 피부에 침투할 수 있는 본 발명의 히알루로난-포스파티딜에탄올아민 결합체(HA-PE-1)의 양을 정량화한 그래프이다. 이 그래프는 도 9에 나타낸 현미경 사진을 정량화한다.
도 11은 본 발명의 변형된 히알루로난 조성물의 적용이 적용 부위에 표피 내에서 국부적으로 남아있는 것을 설명하는 현미경 사진이다. 히알루로난 단독 적용은 표피에서 히알루로난의 어떠한 축척도 초래하지 못한다. 적용 가장자리는 화살표로, 적용 부위는 파선 화살표로 나타내었다.
도 12는 도 11의 마우스 피부에서 본 발명의 히알루로난을 처리 및 처리하지 않는 부위의 수준을 정량화한 그래프이다.
도 13은 본 발명의 히알루로난 조성물(HA-PE-2)은 피부 장벽을 침투할 수 있고, RHAMM 히알루로난 수용체(RHAMM-/- 마우스)가 없는 마우스 교배에서 표피 내에서 결합할 수 있는 것을 나타내는 현미경 사진 및 정량화한 그래프이다. 각 영상에서 각질형성세포 층은 화살표로 나타내었다.
도 14는 본 발명의 히알루로난 조성물(HA-PE-2)은 피부 장벽을 침투할 수 있고, RHAMM 또는 CD44 히알루로난 수용체(RHAMM-/-:CD44-/- 마우스)가 없는 마우스 교배에서 표피 내에서 결합할 수 있는 것을 나타내는 현미경 사진 및 정량화한 그래프이다. 각 영상에서 각질형성세포 층은 화살표로 나타내었다.
도 15는 본 발명의 히알루로난-포스파티딜에탄올아민-결합체(HA-PE-2) 및 종래의 기술을 이용하여 제조된 미립자 지질화 글리코사미노글리칸의 현미경 사진이다.
도 16은 마우스에 국소 적용 후, 본 발명의 히알루로난-포스파티딜에탄올아민 결합체(HA-PE-2)의 피부 장벽을 통한 84kDa 단백질(GST-표시된 RHAMM) 및 26 KDa 단백질(GST)을 전달하는 능력을 설명하는 현미경 사진이다. 각질형성세포 층은 "∧"로 나타내었고, 밑에 있는 근육 층은 화살표로 나타내었다.
도 17은 마우스에 본 발명의 히알루로난-포스파티딜에탄올아민-결합체 (HA-PE-2)의 국소 적용 후, 피부 장벽을 통한 GST-RHAMM, 84KDa 단백질의 전달에 대한 도 16의 현미경 사진을 정량화한 그래프이다.
Claims (104)
여기서 변형될 글리코사미노글리칸은 히알루로난, 히알루로난 유도체, 헥소사민에 결합된 우론산(uronic acid) 또는 헥소오스(hexose)의 반복 이당류 단위로 구성된 다당류, 또는 이의 유도체이며;
변형될 글리코사미노글리칸은 2 kDa 내지 2,500 kDa 범위의 분자량을 가지며;
지질 성분은 글리코사미노글리칸에 지질의 공유결합을 허여하는 이의 극성 머리-기 위에 작용기를 함유하면, 하나 이상의 자연적으로 발생하거나 또는 합성적으로 유도된 지방산, 글리세로지질, 인지질, 스핑고지질, 스테롤 지질, 프레놀 지질, 또는 이의 유도체를 포함하며; 및
변형된 글리코사미노글리칸은 거기에 적용되었을 때 피부 장벽 또는 점막을 침투할 수 있으며,
변형된 글리코사미노글리칸은 글리코사미노글리칸이 지질 성분과 반응하여 형성되는, 글리코사미노글리칸 조성물.
여기서 글리코사미노글리칸 조성물은 1~15%의 반복 이당류 단량체 단위의 글리코사미노글리칸에 지질 성분의 공유결합을 통해 변형된 글리코사미노글리칸을 포함하며;
글리코사미노글리칸은 히알루로난, 히알루로난 유도체, 헥소사민에 결합된 우론산 또는 헥소오스의 반복 이당류 단위로 구성된 다당류, 또는 이의 유도체를 포함하며;
변형될 글리코사미노글리칸은 2 kDa 내지 2,500 kDa 범위의 분자량을 가지며;
지질 성분은 글리코사미노글리칸에 지질의 공유결합을 허여하는 이의 극성 머리기 위에 작용기를 함유하면, 하나 이상의 자연적으로 발생하거나 또는 합성적으로 유도된 지방산, 글리세로지질, 인지질, 스핑고지질, 스테롤 지질, 프레놀 지질, 또는 이의 유도체를 포함하며; 및
변형된 글리코사미노글리칸은 거기에 적용되었을 때 피부 장벽 또는 점막을 침투할 수 있으며,
변형된 글리코사미노글리칸은 글리코사미노글리칸이 지질 성분과 반응하여 형성되는, 제제.
변형될 글리코사미노글리칸을 활성화제로 처리하여 글리코사미노글리칸과 지질 성분의 공유결합을 용이하게 하는 단계;
활성화된 글리코사미노글리칸과 지질 성분을 혼합하는 단계; 및
활성화된 글리코사미노글리칸과 지질 성분을 반응시켜 글리코사미노글리칸에 지질 성분을 공유결합시키는 단계,
여기서, 활성화제는 반응에서 제한 시약이고, 1 내지 15%의 이당류 단량체 단위의 글리코사미노글리칸에 지질 성분의 공유결합을 용이하게 하는데 충분한 양을 가하는 것을 특징으로 하는, 글리코사미노글리칸 조성물의 제조방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2703532A CA2703532C (en) | 2010-05-10 | 2010-05-10 | Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications |
CA2,703,532 | 2010-05-10 | ||
PCT/CA2011/000512 WO2011140630A1 (en) | 2010-05-10 | 2011-05-04 | Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130113325A true KR20130113325A (ko) | 2013-10-15 |
KR101831215B1 KR101831215B1 (ko) | 2018-04-04 |
Family
ID=44912981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020127032320A Expired - Fee Related KR101831215B1 (ko) | 2010-05-10 | 2011-05-04 | 화장품 및 의약품 적용의 사용에 적합한 국소 투여된, 피부-침투성 글리코사미노글리칸 제형 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20130059769A1 (ko) |
EP (1) | EP2569364B1 (ko) |
JP (1) | JP6120283B2 (ko) |
KR (1) | KR101831215B1 (ko) |
CN (2) | CN103080204B (ko) |
AU (1) | AU2011252695B2 (ko) |
BR (1) | BR112012028592A2 (ko) |
CA (1) | CA2703532C (ko) |
RU (1) | RU2637443C2 (ko) |
WO (1) | WO2011140630A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210127844A (ko) * | 2020-04-14 | 2021-10-25 | 코스맥스 주식회사 | 저분자 콜라겐, 엘라스틴 및 글리코사미노글리칸을 포함하는 화장료 조성물 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014001148A (ja) * | 2012-06-15 | 2014-01-09 | Picaso Cosmetic Laboratory Ltd | 線維芽細胞増殖促進剤 |
ITMI20130354A1 (it) | 2013-03-08 | 2014-09-09 | Again Life Italia Srl | Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie. |
US9763969B2 (en) | 2013-04-03 | 2017-09-19 | Cedars-Sinai Medical Center | Treatment of inflammatory conditions with hyaluronan disaccharide |
WO2017180788A1 (en) * | 2016-04-12 | 2017-10-19 | Illustris Pharmaceuticals, Inc. | Compositions for topical application of compounds |
IL278370B2 (en) | 2018-05-03 | 2024-02-01 | Collplant Ltd | Dermal fillers and their uses |
US20210000910A1 (en) | 2019-07-03 | 2021-01-07 | Jysk Skin Solutions Pte Ltd | Topical compositions |
CN110339223A (zh) * | 2019-08-06 | 2019-10-18 | 无锡市新吴区新安街道社区卫生服务中心 | 一种缓解颈椎病症状的喷雾剂制备方法 |
US20210106506A1 (en) * | 2019-10-11 | 2021-04-15 | Elc Management Llc | Methods for cosmetic skin remodeling |
CN110755597B (zh) * | 2019-10-24 | 2023-07-07 | 广州市希丽生物科技服务有限公司 | 用于预防和治疗类风湿性关节炎的外用药物组合物 |
CN111249472B (zh) * | 2020-01-16 | 2024-02-23 | 上海交通大学医学院附属第九人民医院 | 一种可经皮给药的透明质酸纳米凝胶及其制备方法 |
CN111166692A (zh) * | 2020-03-18 | 2020-05-19 | 深圳市百吉因生物科技有限公司 | 一种高保湿性组合物 |
JPWO2022163336A1 (ko) | 2021-01-29 | 2022-08-04 | ||
US12083204B2 (en) | 2022-06-02 | 2024-09-10 | L'oreal | Topical composition for homeostatic delivery of nitric oxide and uses thereof |
CN117137830B (zh) * | 2023-11-01 | 2024-02-13 | 杭州湃肽生化科技有限公司 | 一种皮肤修复组合物及其应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4009282A (en) * | 1973-12-17 | 1977-02-22 | The Regents Of The University Of Michigan | Treatment of proliferating skin diseases with prostaglandins |
US5733892A (en) * | 1990-07-24 | 1998-03-31 | Seikagaku Corporation | Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same |
JP2997018B2 (ja) * | 1990-07-24 | 2000-01-11 | 生化学工業株式会社 | 燐脂質又は脂質結合グリコサミノグリカン |
DE69124590T2 (de) * | 1990-07-24 | 1997-06-12 | Seikagaku Kogyo K K Seikagaku | Glykosaminoglykan gemischt mit phospholipid oder lipid, seine herstellung und krebszellenmetastaseninhibitor |
JP3714683B2 (ja) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
JP3615346B2 (ja) * | 1997-02-18 | 2005-02-02 | 株式会社ノエビア | 皮膚外用剤 |
JP3032824B1 (ja) * | 1999-01-28 | 2000-04-17 | 東京医科歯科大学長 | 骨誘導促進剤 |
US7393938B2 (en) * | 2000-01-10 | 2008-07-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
US20060189568A1 (en) * | 2000-01-10 | 2006-08-24 | Saul Yedgar | Use of lipid conjugates in the treatment of infection |
JP4876334B2 (ja) * | 2001-06-06 | 2012-02-15 | 日油株式会社 | ヒアルロン酸産生能増強剤およびその用途 |
JP4537057B2 (ja) * | 2001-08-14 | 2010-09-01 | テルアビブ・ユニバーシティ・フューチャー・テクノロジー・デベロップメント・エルピー | 脂質化グリコサミノグリカン粒子ならびに診断及び処置のための薬物及び遺伝子送達におけるその使用 |
US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
WO2004003545A1 (en) * | 2002-07-01 | 2004-01-08 | Tufts University | Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
EP1681306B1 (en) * | 2003-10-29 | 2013-02-20 | Teijin Limited | Hyaluronic acid compound, hydrogel thereof and material for treating joint |
WO2006050246A2 (en) * | 2004-11-02 | 2006-05-11 | Tel-Aviv University Future Technology Development L.P. | Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles, their manufacturing and their use for diagnostics and therapy |
JP4832007B2 (ja) | 2005-06-13 | 2011-12-07 | 帝人株式会社 | グリコサミノグリカン誘導体の製造法 |
CN1742623A (zh) * | 2005-07-13 | 2006-03-08 | 凌沛学 | 透明质酸磷脂复合物及其制备方法 |
WO2007043702A1 (en) * | 2005-10-12 | 2007-04-19 | Seikagaku Corporation | Agent for applying to mucosa and method for production thereof |
US20080183282A1 (en) | 2006-03-09 | 2008-07-31 | Saul Yedgar | Use of lipid conjugates for the coating of stents and catheters |
DE102007028360B4 (de) * | 2007-06-15 | 2016-04-14 | Marcus Asam | Wirkstoffkombination für kosmetische Zubereitungen |
JP2011508746A (ja) * | 2007-12-26 | 2011-03-17 | マーク エー. ピンスカイ | 改善されたスキンケアのためのコラーゲン剤形 |
US8632803B2 (en) * | 2008-02-27 | 2014-01-21 | Ramot At Tel-Aviv University Ltd. | System for delivery of protein in insoluble fibrillar or aggregate form |
-
2010
- 2010-05-10 CA CA2703532A patent/CA2703532C/en active Active
-
2011
- 2011-05-04 CN CN201180034053.XA patent/CN103080204B/zh not_active Expired - Fee Related
- 2011-05-04 US US13/696,887 patent/US20130059769A1/en not_active Abandoned
- 2011-05-04 CN CN201711123324.4A patent/CN107814853A/zh active Pending
- 2011-05-04 JP JP2013509410A patent/JP6120283B2/ja not_active Expired - Fee Related
- 2011-05-04 RU RU2012152562A patent/RU2637443C2/ru not_active IP Right Cessation
- 2011-05-04 EP EP11780002.9A patent/EP2569364B1/en not_active Not-in-force
- 2011-05-04 KR KR1020127032320A patent/KR101831215B1/ko not_active Expired - Fee Related
- 2011-05-04 AU AU2011252695A patent/AU2011252695B2/en not_active Ceased
- 2011-05-04 WO PCT/CA2011/000512 patent/WO2011140630A1/en active Application Filing
- 2011-05-04 BR BR112012028592A patent/BR112012028592A2/pt not_active Application Discontinuation
-
2015
- 2015-06-01 US US14/727,257 patent/US10131717B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210127844A (ko) * | 2020-04-14 | 2021-10-25 | 코스맥스 주식회사 | 저분자 콜라겐, 엘라스틴 및 글리코사미노글리칸을 포함하는 화장료 조성물 |
Also Published As
Publication number | Publication date |
---|---|
AU2011252695B2 (en) | 2016-04-21 |
CA2703532A1 (en) | 2011-11-10 |
AU2011252695A1 (en) | 2013-01-10 |
CN107814853A (zh) | 2018-03-20 |
JP6120283B2 (ja) | 2017-04-26 |
RU2012152562A (ru) | 2014-06-20 |
EP2569364B1 (en) | 2018-06-13 |
US20150368373A1 (en) | 2015-12-24 |
KR101831215B1 (ko) | 2018-04-04 |
EP2569364A4 (en) | 2013-10-02 |
US10131717B2 (en) | 2018-11-20 |
WO2011140630A1 (en) | 2011-11-17 |
CN103080204B (zh) | 2017-12-12 |
CA2703532C (en) | 2018-05-01 |
BR112012028592A2 (pt) | 2018-05-08 |
US20130059769A1 (en) | 2013-03-07 |
RU2637443C2 (ru) | 2017-12-04 |
JP2013526620A (ja) | 2013-06-24 |
CN103080204A (zh) | 2013-05-01 |
EP2569364A1 (en) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101831215B1 (ko) | 화장품 및 의약품 적용의 사용에 적합한 국소 투여된, 피부-침투성 글리코사미노글리칸 제형 | |
Witting et al. | Interactions of hyaluronic acid with the skin and implications for the dermal delivery of biomacromolecules | |
JP6006812B2 (ja) | 改善されたスキンケアのための組成物および方法 | |
JP4572003B2 (ja) | 自然老化または老化亢進性(日光皮膚炎、汚染)の際の、瘢痕化、保湿化および皮膚外観改良用のペプチドの化粧品としてのまたは皮膚薬品としての使用 | |
EP3103485A1 (en) | Material comprising a polymer capable of forming a hydrogel and nanoparticles | |
KR20180123036A (ko) | 보습용 조성물 및 이의 용도 | |
WO2014044808A2 (en) | Fast-penetration cosmetic dermal filler for topical application | |
ES2617262T3 (es) | Composición cosmética y farmacéutica que comprende 6-fosfato de N-acetilglucosamina y un compuesto de la familia de la vitamina A | |
US12311048B2 (en) | Crosslinked materials | |
JP6000511B2 (ja) | 酸性多糖の酪酸−ギ酸混合エステル、ならびに肌用化粧品としてのその調製および使用 | |
ITMI20111806A1 (it) | Composizione per il trattamento delle lesioni cutanee | |
KR102118226B1 (ko) | 레티노이드를 함유하는 o/w-에멀젼-유형 국소 약학 조성물 | |
Morganti | Chitin Nanofibrils in skin treatment | |
CN104703583A (zh) | 经修饰的透明质酸衍生物及其用途 | |
WO2016126947A2 (en) | Subcutaneous complex and single-component ecm compositing for induction of hair growth and follicular regeneration | |
JP2006342351A (ja) | 皮膚水分含有量を調節および改善するためのスクレログルカン解重合物 | |
US20180036220A1 (en) | Hyaluronic acid particles for cosmetic or dermatological uses | |
EP3158999B1 (en) | Cell mobilization agent containing lysophospholipid with retinoic acid introduced | |
AU2013270451B2 (en) | Compositions and methods for improved skin care | |
FR2932381A1 (fr) | Composition cosmetique ou pharmaceutique contenant une association de hyaluronane reticule ou non reticule et d'heparine et/ou un ou plusieurs derives heparinoides pour voie topique et injectable | |
Israel | Topical formulations for disease treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20121210 Patent event code: PA01051R01D Comment text: International Patent Application |
|
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20130118 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20160504 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170307 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20171114 |
|
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180214 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20180214 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20210215 Start annual number: 4 End annual number: 4 |
|
PC1903 | Unpaid annual fee |